Kymab

History

2021: Sanofi purchased Kymab for $1.1 billion

On January 11, 2021 Sanofi announced Kymab acquisition. The cost of the transaction is $1.1 billion. At the same time to conditions the agreement additional payments at the rate to $350 million in case of achievement of certain indicators by the British developer of immunooncological medicines are provided. About what tasks there is a speech, it is not specified.

As soon as the transaction is closed (it is expected that this will occur by the end of June, 2021), Sanofi will acquire the rights to the medicine Kymab KY1005 using monoclonal antibodies for treatment of a broad spectrum of the inflammatory diseases and diseases connected with the immune system. By January 11, 2021 this medicine went through an intermediate stage of clinical trials of the phase IIa.

Sanofi purchased Kymab for $1.1 billion

Kymab portfolio also includes medicine for fight against cancer of KY1044 which by January, 2021 is at a stage of I/II of clinical development.

As notes Reuters agency, Sanofi was late with entry into the market of an immunotherapy (the company made it at the beginning of 2010) — the medicines activating the immune system of an organism for the attack of tumor cells. Now the company tries to make up for lost time and focused on development of several products which as the pharmproizvoditel hopes, will provide it a share in the market of drugs for cancer of $100 billion.

Acquisition of Kymab adds to our portfolio of KY1005, the first in the class medicine for treatment of a number of immune and inflammatory diseases. The new mechanism of action can provide treatment of patients with the non-optimal answer to available methods of treatment — Paul Hudson, the CEO of Sanofi told. — We understand from our current work in the field of immunological diseases, it is how important to find the correct treatment for each patient.[1]

Notes